We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Read MoreHide Full Article
Dianthus Therapeutics, Inc. (DNTH - Free Report) shares soared 5.6% in the last trading session to close at $83.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 43.8% gain over the past four weeks.
This rise in share price is attributed to positive investor expectations around its pipeline. The stock has been surging over the past month after the company announced an early “GO” decision in the late-stage CAPTIVATE study evaluating claseprubart for a rare autoimmune disease called chronic inflammatory demyelinating polyneuropathy (CIDP). This decision came ahead of schedule as the company hit its interim responder goals.
Dianthus’ shares received an additional boost last week after the FDA agreed to several proposed changes related to clinical development of claseprubart, including updates to screening criteria, routine lab work and autoimmune safety monitoring. These changes apply to all ongoing and future studies.
This company is expected to post quarterly loss of $1.17 per share in its upcoming report, which represents a year-over-year change of -42.7%. Revenues are expected to be $0.55 million, down 53% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Dianthus Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 27.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on DNTH going forward to see if this recent jump can turn into more strength down the road.
Dianthus Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Foghorn Therapeutics Inc. (FHTX - Free Report) , finished the last trading session 8.1% higher at $4.78. FHTX has returned -23.3% over the past month.
For Foghorn Therapeutics, the consensus EPS estimate for the upcoming report has changed -7.7% over the past month to -$0.28. This represents a change of +6.7% from what the company reported a year ago. Foghorn Therapeutics currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH - Free Report) shares soared 5.6% in the last trading session to close at $83.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 43.8% gain over the past four weeks.
This rise in share price is attributed to positive investor expectations around its pipeline. The stock has been surging over the past month after the company announced an early “GO” decision in the late-stage CAPTIVATE study evaluating claseprubart for a rare autoimmune disease called chronic inflammatory demyelinating polyneuropathy (CIDP). This decision came ahead of schedule as the company hit its interim responder goals.
Dianthus’ shares received an additional boost last week after the FDA agreed to several proposed changes related to clinical development of claseprubart, including updates to screening criteria, routine lab work and autoimmune safety monitoring. These changes apply to all ongoing and future studies.
This company is expected to post quarterly loss of $1.17 per share in its upcoming report, which represents a year-over-year change of -42.7%. Revenues are expected to be $0.55 million, down 53% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Dianthus Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 27.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on DNTH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Dianthus Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Foghorn Therapeutics Inc. (FHTX - Free Report) , finished the last trading session 8.1% higher at $4.78. FHTX has returned -23.3% over the past month.
For Foghorn Therapeutics, the consensus EPS estimate for the upcoming report has changed -7.7% over the past month to -$0.28. This represents a change of +6.7% from what the company reported a year ago. Foghorn Therapeutics currently has a Zacks Rank of #3 (Hold).